Because of the uncertainty surrounding the Trump administration's tariff war with China, supply chain advisors are cautioning firms that import drug products and ingredients from China to take a wait-and-see approach.
There's no point yet for firms to try to avoid tariffs by building manufacturing facilities in the US or even rerouting supply chains
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?